Stability of ketoconazole, metolazone, metronidazole, procainamide hydrochloride, and spironolactone in extemporaneously compounded oral liquids

被引:22
|
作者
Allen, LV [1 ]
Erickson, MA [1 ]
机构
[1] PADDOCK LABS INC, MINNEAPOLIS, MN USA
关键词
anti-infective agents; antifungals; capsules; cardiac drugs; cherry syrup; compounding; containers; diuretics; incompatibilities; ketoconazole; liquids; metolazone; metronidazole; polyethylene terephthalate; powders; procainamide hydrochloride; spironolactone; stability; storage; suspending agents; tablets; temperature; vehicles;
D O I
10.1093/ajhp/53.17.2073
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The stability of drugs commonly prescribed for use in oral liquid dosage forms but not commercially available as such was studied. Ketoconazole 20 mg/mL, metolazone 1 mg/mL, metronidazole 50 mg/mL, procainamide hydrochloride 50 mg/mL, and spironolactone 25 mg/mL were prepared in a 1:1 mixture of Ora-Sweet and Ora-Plus (Paddock Laboratories), a 1:1 mixture of Ora-Sweet SF and Ora-Plus (Paddock Laboratories), and cherry syrup and placed in 120-mL polyethylene terephthalate bottles. The sources of the drugs were powder, capsules, and tablets. Six bottles were prepared per liquid; three were stored at 5 degrees C and three at 25 degrees C, all in the dark. A sample was removed from each bottle immediately after preparation and at intervals up to 60 days and analyzed for drug concentration by stability-indicating high-performance liquid chromatography. At least 93% of the initial drug concentration was retained in all the oral liquids for up to 60 days. There were no substantial changes in the appearance or odor of the liquids, or in the pH. Ketoconazole 20 mg/mL, metolazone 1 mg/mL, metronidazole 50 mg/mL, procainamide hydrochloride 50 mg/mL, mt, and spironolactone 25 mg/mL were stable for up to 60 days at 5 and 25 degrees C in three extemporaneously compounded oral liquids.
引用
收藏
页码:2073 / 2078
页数:6
相关论文
共 50 条
  • [21] Stability of zonisamide in extemporaneously compounded oral suspensions
    Abobo, Cyril V.
    Wei, Bo
    Liang, Dong
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2009, 66 (12) : 1105 - 1109
  • [22] Stability of nifedipine in an extemporaneously compounded oral solution
    Dentinger, PJ
    Swenson, CF
    Anaizi, NH
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2003, 60 (10) : 1019 - 1022
  • [23] STABILITY OF ATENOLOL IN AN EXTEMPORANEOUSLY COMPOUNDED ORAL LIQUID
    GARNER, SS
    WIEST, DB
    REYNOLDS, ER
    AMERICAN JOURNAL OF HOSPITAL PHARMACY, 1994, 51 (04): : 508 - 511
  • [24] Stability of famotidine in an extemporaneously compounded oral liquid
    Dentinger, PJ
    Swenson, CF
    Anaizi, NM
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2000, 57 (14) : 1340 - 1342
  • [25] STABILITY OF URSODIOL IN AN EXTEMPORANEOUSLY COMPOUNDED ORAL LIQUID
    JOHNSON, CE
    NESBITT, J
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 1995, 52 (16) : 1798 - 1800
  • [26] Stability of an extemporaneously compounded minoxidil oral suspension
    Song, Yunmei
    Chin, Zen Whey
    Ellis, David
    Lwin, Ei Mon Phyo
    Turner, Sean
    Williams, Desmond
    Garg, Sanjay
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2018, 75 (05) : 309 - 315
  • [27] Stability of pantoprazole in an extemporaneously compounded oral liquid
    Dentinger, PJ
    Swenson, CF
    Anaizi, NH
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2002, 59 (10) : 953 - 956
  • [28] Stability of levofloxacin in an extemporaneously compounded oral liquid
    VandenBussche, HL
    Johnson, CE
    Fontana, EM
    Meram, JM
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 1999, 56 (22) : 2316 - 2318
  • [29] STABILITY OF AN EXTEMPORANEOUSLY COMPOUNDED BACLOFEN ORAL LIQUID
    JOHNSON, CE
    HART, SM
    AMERICAN JOURNAL OF HOSPITAL PHARMACY, 1993, 50 (11): : 2353 - 2355
  • [30] Stability of Dapsone in Extemporaneously Compounded Oral Suspensions
    Alarie, Hugo
    Friciu, M. Mihaela
    Leclair, Gregoire
    CANADIAN JOURNAL OF HOSPITAL PHARMACY, 2018, 71 (02): : 152 - 154